Horizon Pharma (HZNP) Tops Q3 EPS by 30c; Boosts FY15 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Horizon Pharma plc Announces Exceptional Third-Quarter 2015 Financial Results and Significantly Raises Full-Year 2015 Sales and Adjusted EBITDA Guidance
November 6, 2015 7:00 AM ESTDUBLIN, IRELAND -- (Marketwired) -- 11/06/15 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its third-quarter 2015 financial results today.
Quarterly Financial Highlights
(in millions except for per share amounts and % % percentages) Q3 15 Q3 14 Change 9M 15 9M 14 Change --------- --------- ------- --------- --------- ------- Net sales $ 226.5 $ 75.1 202 $ 512.5 $ 193.1 165 Net income (loss) 3.3 2.1 57 15.5 (232.0) NM Adjusted non-GAAP net income 117.0 19.4 503 203.4 46.2 340 Adjusted EBITDA 131.1 22.1 493 239.7 52.3 358 Earnings (loss) per share - basic $ 0.02 $ 0.03 -33 $ 0.11 $ (3.17) NM Adjusted non-GAAP earnings per share - basic 0.74 0.25 196 1.40 0.63 122 Earnings (loss)... More
